Drugs / Yunnan Baiyao
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01652625 | Mar 2010 → Mar 2011 | aphthous stomatitis | Peking University | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06197412 | Dec 2023 → Dec 2025 | — | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06062576 | Dec 2023 → Dec 2024 | — | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05765747 | Apr → Dec 2023 | — | Peking University Third Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yunnan Baiyao | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06062576 ↗ |
| Known as | YNBY | “This multicentre, randomised, open-label, blinded-endpoint trial investigated the efficacy and safety of Yunnan Baiyao (YNBY), a traditional Chinese medicine, as an adjunctive...” PMID 42236253 ↗ Jul 2026 |
| Modality | Traditional medicine (herbal / TCM) | “Yunnan Baiyao is a well-known traditional Chinese medicine, formulated in a powder or capsule form.” NCT01652625 ↗ |